Annexin Pharmaceuticals AB

Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.

ANNX | ST

Overview

Corporate Details

ISIN(s):: SE0009664154
LEI:: 5493000JP703HGPJEX27
Country:: Sweden
Address:: KAMMAKARGATAN 48, 111 60 Stockholm
Website:: https://annexinpharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Annexin Pharmaceuticals AB is a clinical-stage biotechnology company focused on the therapeutic protein Annexin A5. The company's lead drug candidate, ANXV, is a recombinant human Annexin A5 that targets phosphatidylserine (PS), a lipid exposed on the surface of stressed or damaged cells. By binding to PS, ANXV acts as a cell protector and immunomodulator, counteracting tissue injury and regulating immune responses. The company's primary focus is on developing ANXV for indications with significant unmet medical needs, including Retinal Vein Occlusion (RVO), for which it is currently in Phase 2 clinical trials, and oncology. ANXV has potential as a first-in-class treatment across a broad range of vascular, inflammatory, and cancerous diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Annexin Pharmaceuticals AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Annexin Pharmaceuticals AB

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Annexin Pharmaceuticals AB via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Hugel, Inc. Global provider of medical aesthetic solutions like botulinum toxin and HA fillers.	South Korea	145020
Human Stem Cells Institute PJSC A biotech investor developing gene therapy, regenerative medicine, and genetic services.	Russian Federation	ISKJ
HUMASIS CO., LTD. Develops & manufactures rapid in-vitro diagnostic test kits & instruments for global POCT markets.	South Korea	205470
Humedix Co., Ltd. Develops hyaluronic acid-based pharma, aesthetics, medical devices, and offers CMO services.	South Korea	200670
HUONS CO., LTD. Global healthcare company providing pharmaceuticals, medical devices, and wellness products.	South Korea	243070
Huons Global Co., Ltd. Develops pharmaceuticals, medical devices, cosmetics, and health foods for the global market.	South Korea	084110
Hutchmed (China) Limited	Hong Kong	N/A
HWAIL PHARM. CO., LTD Develops and manufactures APIs, finished drugs, and functional ingredients for healthcare.	South Korea	061250
Hyloris Pharmaceuticals SA A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.	Belgium	HYL
HYUNDAI BIOLAND Co.,Ltd. Develops natural biomaterials for cosmetics, nutraceuticals, and regenerative medicine globally.	South Korea	052260